Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CM
Alnylam Pharmaceuticals (ALNY) reported five-year data from the HELIOS-B study, showing that early treatment with AMVUTTRA (vutrisiran) in ATTR-CM patients led to better long-term outcomes, including a 48% reduction in mortality and cardiovascular events in the monotherapy group. The study also showed improved quality of life and stability in cardiac biomarkers. The safety profile remained consistent. The findings were presented at the American Heart Association Scientific Sessions 2026.
How this was made
The 30-second read
Why it matters
The data reinforce vutrisiran's clinical value, likely supporting price appreciation and encouraging analyst upgrades.
Market read
First‑time disclosure of robust long‑term efficacy for an approved drug, a material catalyst for ALNY.
What to watch
Potential competition from other TTR‑silencing agents and payer coverage decisions.
Background
Alnylam presented the five‑year data at the American Heart Association Scientific Sessions 2026.
Ticker impact
Alnylam disclosed five-year HELIOS‑B trial results showing significant mortality and event reductions for vutrisiran in ATTR‑CM patients.
upward pressure as investors price in improved survival and event outcomes.
Phase‑III‑like data with 40‑50% risk reductions are material for a biotech with an approved product.
Market effects
Strengthens the ATTR‑CM therapeutic niche and may boost peer biotech valuations.
U.S. biotech sector could see modest gains on the back of the data.
Highlights RNA‑silencing approach, relevant to global investors tracking gene‑therapy advances.
Counterpoint
If longer‑term safety or reimbursement issues emerge, the rally could be limited.
Key entities
- companyAlnylam Pharmaceuticals, Inc.
US‑listed biotech developing RNAi therapeutics.
